Oranges, Hesperidin and Blood Vessels

Table of Contents

1. What Hesperidin Is, and Where It Hides
2. Why the Sweet Orange Is Not the Grapefruit
3. The Bioavailability Problem
4. The Endothelium and Why It Is Measured
5. The Morand Trial: Orange Juice, and Hesperidin Alone
6. Metabolic Syndrome: The Rizza Trial
7. The Null Result Worth Reading: Salden 2016
8. The Largest Blood-Pressure Trial: Valls 2021
9. Inflammation and Blood-Orange Juice
10. What the Systematic Reviews Conclude
11. The Population Studies, Read Carefully
12. Practical: Getting Hesperidin From Fruit
13. Supplements, Safety and Honest Expectations
14. Key Research Papers
15. Connections
16. Featured Videos

What Hesperidin Is, and Where It Hides

Hesperidin is a flavanone glycoside — a flavonoid core (called hesperetin) with a two-sugar tail attached. The sugar tail is a rutinoside, and it matters enormously for what happens in your gut, as the next-but-one section explains. Hesperidin is the signature flavonoid of the sweet orange, and it is present in large amounts.

Its distribution inside the fruit is the practical point. Hesperidin sits mainly in:

• The albedo — the spongy white pith between the coloured peel and the flesh. This is the richest part.
• The segment membranes — the thin, slightly chewy walls around each group of juice sacs.
• The peel, including the zest.

The juice itself carries far less by weight than the pith does — though because people drink a lot more juice than they eat pith, juice is still the main dietary source for most Western populations. If you meticulously strip every strand of white from an orange before eating it, you are discarding most of its hesperidin. Leaving some pith on is free, and eating the fruit with its membranes intact rather than supreming it into naked segments is free too.

A second flavanone, narirutin, accompanies hesperidin in sweet oranges in smaller amounts, and there are traces of others. Blood oranges add anthocyanins on top — a different class of compound entirely, discussed below.

Back to Table of Contents

Why the Sweet Orange Is Not the Grapefruit

People often lump citrus flavonoids together, and there is one distinction worth keeping straight because it has real clinical consequences.

Naringin and its aglycone naringenin are the characteristic bitter flavanones of grapefruit, pummelo and the bitter Seville orange. The sweet orange contains only small amounts. So when you read about "citrus flavonoids", check which fruit is being discussed — hesperidin research and naringenin research are largely separate literatures.

More importantly, the notorious grapefruit–medication interaction is not caused by flavonoids at all. It is caused by furanocoumarins, which inhibit the intestinal enzyme CYP3A4 and let certain drugs build up to higher-than-intended blood levels. Grapefruit has them. The bitter Seville orange has them — Malhotra and colleagues showed Seville orange juice interfering with the blood-pressure drug felodipine much as grapefruit does. The sweet orange is essentially free of them and does not cause that interaction. Your morning navel is not the grapefruit problem, and this is one of the most useful things on this page for anyone who takes a medication with a grapefruit warning on the label.

Back to Table of Contents

The Bioavailability Problem

Hesperidin is not absorbed in the small intestine, and understanding why explains most of the messiness in the trial literature.

The rutinoside sugar tail is too bulky for the small-intestinal transporters, and human enzymes cannot cut it off. The molecule therefore travels all the way to the colon, where gut bacteria carrying an α-rhamnosidase snip off the rhamnose sugar, then a β-glucosidase removes the glucose, freeing the aglycone hesperetin, which the colonic wall can absorb. Three consequences follow directly:

• Absorption is slow. Plasma hesperetin peaks roughly five to seven hours after you drink orange juice, not one or two. A study looking for an effect at the wrong time point will miss it — which is precisely what happened in the fasting measurements described below.
• Absorption is variable between people. It depends on which bacteria you are carrying. Two people drinking identical glasses of juice can end up with markedly different plasma hesperetin. Mas-Capdevila and colleagues review this microbiota dependence in detail, and it is the leading explanation for why hesperidin trials disagree with each other.
• Chemistry can bypass the bottleneck. Nielsen and colleagues tested an enzymatically modified form, hesperetin-7-glucoside, in a randomised crossover trial and found it substantially more bioavailable than ordinary hesperidin — because the simpler glucoside can be handled in the small intestine without waiting for the colon.

Anyone reading the trial literature should hold onto this. A "negative" hesperidin trial may be a trial in which not enough hesperetin reached the bloodstream, and a positive one may be a trial that happened to measure at the right hour in people with the right microbes. That is not a get-out clause for believing whatever you like — it is a reason to weight the larger and longer trials most heavily.

Back to Table of Contents

The Endothelium and Why It Is Measured

Almost every hesperidin trial measures the same thing, so it is worth knowing what it is.

The endothelium is the single-cell lining of every blood vessel in your body — not a passive pipe wall but an active organ that releases nitric oxide to relax the muscle in the vessel wall, controls how sticky the surface is to white blood cells, and regulates clotting. When it stops working properly (endothelial dysfunction), vessels do not dilate as they should, white cells adhere and burrow in, and that is the opening move of atherosclerosis. Endothelial dysfunction shows up years before any narrowing does, which is why it is such an attractive early marker.

Two measurements recur:

• Flow-mediated dilation (FMD) — a blood-pressure cuff is inflated on the upper arm to stop flow, then released. The surge of blood shears the vessel lining, healthy endothelium responds by releasing nitric oxide, and the brachial artery widens. Ultrasound measures how much, as a percentage. Higher is better; FMD tracks with future cardiovascular risk.
• Microvascular reactivity — the same idea in the tiny vessels of the skin, usually with laser Doppler and a vasodilator applied to the skin surface.

Also common are circulating adhesion molecules (sVCAM-1, sICAM-1, sE-selectin, P-selectin), which the endothelium sheds into the blood when it is in an activated, inflamed state. Lower is better.

Back to Table of Contents

The Morand Trial: Orange Juice, and Hesperidin Alone

The trial that put hesperidin on the map is Morand and colleagues' 2011 study in the American Journal of Clinical Nutrition, and its design is the reason it carries weight.

Twenty-four healthy but moderately overweight men aged 50 to 65 went through three four-week periods in randomised, controlled, crossover order. In each period they drank 500 mL a day of one of: orange juice; a control drink plus hesperidin (matched to the amount in the juice); or the control drink plus placebo. That third arm is the clever part — it separates "orange juice does something" from "hesperidin does something", which almost no earlier study had managed.

The findings, stated precisely:

• Diastolic blood pressure was significantly lower after four weeks of orange juice, and equally after four weeks of the control drink plus hesperidin, compared with placebo (P = 0.02). Hesperidin on its own reproduced the juice's effect.
• Fasting microvascular reactivity was not significantly affected. Measured after an overnight fast — that is, long after any hesperetin had cleared — there was no difference.
• Postprandial microvascular reactivity did improve significantly (P < 0.05) for both orange juice and hesperidin, when measured at the peak of plasma hesperetin concentration.

The fasting-versus-postprandial split is not a disappointing footnote; it is the most informative part of the result, and it fits the absorption biology exactly. The effect appears when the compound is actually in the blood and is gone when it is not. It also suggests something quietly practical: a benefit that comes and goes with each dose is an argument for eating citrus regularly, not in occasional large amounts.

Back to Table of Contents

Metabolic Syndrome: The Rizza Trial

Rizza and colleagues published a study in 2011 that pairs cell-culture mechanism with a human trial, which is unusual and useful.

In cultured aortic endothelial cells, hesperetin triggered phosphorylation of Src, Akt, AMP kinase and endothelial nitric oxide synthase, producing nitric oxide — and the effect required generation of hydrogen peroxide, an interesting wrinkle since it means the "antioxidant" is signalling through a mild oxidant. Pretreating the cells with hesperetin also reduced how strongly monocytes stuck to them and lowered VCAM-1 expression after an inflammatory stimulus.

The clinical half was a randomised, placebo-controlled, double-blind crossover trial in 24 people with metabolic syndrome, given 500 mg of hesperidin once daily for three weeks. Compared with placebo, hesperidin:

• increased brachial artery flow-mediated dilation from 7.78% to 10.26% (P = 0.02) — a substantial change in a measure that ordinarily moves slowly;
• reduced circulating high-sensitivity C-reactive protein, serum amyloid A and soluble E-selectin.

The authors described it as exploratory, and it is small. But the combination of a plausible mechanism demonstrated in cells and a matching change in people is the sort of coherence that makes a finding worth taking seriously.

Back to Table of Contents

The Null Result Worth Reading: Salden 2016

It would be easy to write this page as a run of positive trials. That would be dishonest, because one of the better-designed studies did not work.

Salden and colleagues randomised 68 overweight individuals to 450 mg/day of hesperidin 2S — a more bioavailable preparation — or placebo for six weeks, measuring FMD, three adhesion molecules and blood pressure at baseline and at the end, both fasting and after a deliberately endothelium-stressing high-fat meal.

The primary result was negative. No significant change in fasting or postprandial FMD was seen in the study population as a whole. There was a trend toward lower sVCAM-1, sICAM-1, P-selectin and both systolic and diastolic blood pressure, but a trend is not a finding. An exploratory subgroup analysis in participants whose baseline FMD was at least 3% did show protection from post-meal endothelial dysfunction and significant reductions in two adhesion molecules — and the authors state plainly that their results were not adjusted for multiplicity, which is exactly the caveat a post-hoc subgroup deserves.

How should a reader weigh this against Morand and Rizza? Sensibly, and without picking a side. The most defensible summary is that hesperidin's effect on endothelial function is real but small and inconsistent — large enough to appear repeatedly in trials of a few dozen people, small enough that a well-run trial of 68 can miss it. That is a completely normal profile for a food compound, and it is a world away from how supplement labels describe it.

Back to Table of Contents

The Largest Blood-Pressure Trial: Valls 2021

The biggest and longest test so far comes from Valls and colleagues in Reus, Spain. It was a randomised, parallel, double-blind, placebo-controlled trial in 159 people with pre-hypertension or stage-1 hypertension, each drinking 500 mL a day for 12 weeks of one of three drinks: a control beverage, ordinary orange juice, or hesperidin-enriched orange juice. Dose-response studies were run at the start and at the end.

The results:

• A single 500 mL dose of the enriched juice lowered systolic blood pressure and pulse pressure.
• After sustained consumption, the changes were larger, and diastolic pressure fell as well (P < 0.05).
• Systolic pressure and pulse pressure decreased in a dose-dependent manner relative to the hesperidin content of the three drinks across the twelve weeks.
• After 12 weeks, four genes related to hypertension (PTX3, NLRP3, NPSR1, NAMPT) were expressed differently in circulating immune cells.

A dose-response relationship in a trial this size is meaningful evidence, and it is consistent with Morand's much smaller diastolic finding a decade earlier. Two honest framings are needed alongside it. First, 500 mL of orange juice a day is a lot of juice — roughly two large glasses, with the sugar load that implies, which is a real trade-off discussed in Fiber, Pectin and Limonoids. Second, blood pressure is a risk marker, not an outcome; no trial has shown that citrus flavanones prevent heart attacks or strokes, and none is likely to be run.

Back to Table of Contents

Inflammation and Blood-Orange Juice

Blood oranges — Moro, Tarocco, Sanguinello — carry everything an ordinary orange does plus anthocyanins, the crimson pigments also found in blueberries and blackberries. The trees only make them when nights are cold, which is why the classic varieties are Sicilian.

Buscemi and colleagues tested red orange juice in adults at increased cardiovascular risk and reported a clear short-term result: after just seven days, flow-mediated dilation improved and normalised, rising from 5.7% to 7.9% (P < 0.005), while high-sensitivity C-reactive protein, interleukin-6 and TNF-α all fell significantly (P < 0.001). Interestingly, plasma nitric oxide concentrations did not change — a reminder that a circulating marker does not always track what is happening in the vessel wall.

A week is a short trial and the participants were a selected high-risk group, so this is a promising signal rather than a settled fact. It does suggest that if you enjoy blood oranges, you are getting a package with an extra active ingredient in it — and the same is true of pink-fleshed Cara Cara navels, whose colour comes from lycopene rather than anthocyanins.

Back to Table of Contents

What the Systematic Reviews Conclude

Two reviews are worth quoting closely, because the difference between what they say and what a supplement label says is instructive.

Pla-Pagà and colleagues (2019) systematically reviewed 12 animal studies and 11 randomised clinical trials of hesperidin against cardiovascular risk biomarkers. In the animal work, chronic flavonoid consumption lowered glucose, total and LDL cholesterol and triglycerides. In the human trials, endothelial function improved, but no conclusive results were observed for the other biomarkers, and the authors concluded that a definitive conclusion cannot be drawn from the existing human evidence. That is the most accurate one-sentence summary of this field available: endothelium yes, everything else not yet.

Testai and Calderone (2017) reviewed citrus flavanones more broadly and set out the plausible mechanisms — nitric oxide signalling, effects on inflammatory pathways, lipid handling — while being clear that the human data are dominated by intermediate markers rather than clinical outcomes.

The pattern is one you will meet again and again in nutrition. Animal studies show broad metabolic effects at doses no human eats. Human trials show a narrow, specific, reproducible effect on one measurable thing. The gap between those two is where most supplement marketing lives.

Back to Table of Contents

The Population Studies, Read Carefully

Large observational cohorts give a different kind of evidence: not what happens when you give someone hesperidin, but what happens over years to people who habitually eat more of it. Two from the same research group are worth setting side by side, because one supports the citrus story and one does not.

• Stroke — supportive. Cassidy and colleagues followed a large cohort of women for 14 years and recorded 1,803 incident strokes. Women in the highest quintile of flavanone intake had a relative risk of ischaemic stroke of 0.81 (95% CI 0.66–0.99, P = 0.04) compared with the lowest. Notably, total flavonoid intake was not associated with stroke — only this subclass was. Citrus fruits and juices, the main dietary source, tended in the same direction without reaching significance (RR 0.90, 95% CI 0.77–1.05).
• Hypertension — not supportive. An earlier analysis by the same group of habitual flavonoid subclass intake and incident hypertension found the protective association with anthocyanins, predominantly from blueberries and strawberries — an 8% lower risk in the top quintile, and 12% in people aged 60 or under. Flavanones showed no association with hypertension in that analysis.

Putting an inconvenient result next to a convenient one is the point. The observational evidence for citrus flavanones is suggestive for ischaemic stroke and absent for developing hypertension, and neither is proof of anything, because people who eat a lot of citrus differ from people who do not in dozens of ways no statistical adjustment fully removes.

Back to Table of Contents

Practical: Getting Hesperidin From Fruit

None of this needs a supplement or a regime. A few habits capture most of what is available:

• Do not peel the pith away. The white layer is where the hesperidin is. Eat the fruit with some of it attached; it is slightly bitter and completely harmless.
• Eat segments whole, membranes and all. Supreming an orange into naked wedges — the restaurant technique — removes the membranes that carry flavanones and fibre both.
• Use the zest. Grated peel carries flavanones and aromatic oils with essentially no sugar. Wash the fruit well first, or buy organic, since surface residues sit on the peel.
• If you drink juice, choose it with pulp, keep the glass small, and have it with food. The trials used 500 mL a day, which is more juice than most people should drink habitually for other reasons.
• Regularly beats occasionally. Because plasma hesperetin rises and falls with each dose, a daily orange is likely to be worth more than four oranges on Sunday.
• Marmalade is not a shortcut. It is made from bitter oranges and does carry flavanones, but the sugar content puts it in the jam category rather than the fruit category.

Two other citrus habits are worth knowing about. Chinese medicine has used aged dried mandarin peel — chen pi — for centuries, sold by vintage year, which is a tradition built entirely around the flavanone-rich part of the fruit. And a strip of orange peel in a stew, a stock or a braise is a European habit that does the same thing incidentally.

Back to Table of Contents

Supplements, Safety and Honest Expectations

Hesperidin supplements exist, typically at 500 mg per capsule, often combined with diosmin and marketed for venous problems such as haemorrhoids and chronic venous insufficiency — a use with its own separate European literature, not covered here. Hesperidin at these doses has a good safety record; the trials above reported no meaningful adverse effects.

Three honest expectations, though:

1. The effect size is small. A few millimetres of mercury on diastolic pressure, or two or three percentage points of flow-mediated dilation. That is worth having as a free side-effect of eating fruit. It is not worth building a health strategy around, and it will not replace a blood-pressure medication.
2. The evidence is for markers, not outcomes. No trial has tested whether hesperidin prevents a heart attack, and none is likely to, because the trial would need thousands of people and many years to detect an effect this size.
3. Whole fruit brings more than the molecule. An orange delivers hesperidin along with vitamin C, folate, potassium, pectin and carotenoids, in quantities and combinations that a capsule does not reproduce. Wherever a compound has been isolated from a food and tested alone, the isolated version has generally underperformed the food. That is the single most repeated lesson of nutrition research over the last thirty years.

If you take a medication with a grapefruit warning: sweet oranges are fine, and bitter Seville oranges and pomelos are not. If you are on a warfarin-type anticoagulant, or you have any concern at all, a pharmacist can check a specific interaction in seconds — that is a genuinely useful conversation rather than a defensive one.

Back to Table of Contents

Key Research Papers

1. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011;93(1):73–80. — doi:10.3945/ajcn.110.004945. Three-arm crossover in 24 overweight men; diastolic blood pressure fell with orange juice and equally with hesperidin alone; postprandial microvascular reactivity improved, fasting did not.
2. Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E782–E792. — doi:10.1210/jc.2010-2879. FMD 7.78% to 10.26% (P = 0.02) on 500 mg/day for three weeks, plus cell-culture mechanism.
3. Salden BN, Troost FJ, de Groot E, et al. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016;104(6):1523–1533. — doi:10.3945/ajcn.116.136960. The honest null: no significant FMD change overall; positive findings confined to an unadjusted exploratory subgroup.
4. Valls RM, Pedret A, Calderón-Pérez L, et al. Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial. Eur J Nutr. 2021;60(3):1277–1288. — doi:10.1007/s00394-020-02279-0. 159 participants, 12 weeks, 500 mL/day; dose-dependent falls in systolic and pulse pressure by hesperidin content.
5. Buscemi S, Rosafio G, Arcoleo G, et al. Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk. Am J Clin Nutr. 2012;95(5):1089–1095. — doi:10.3945/ajcn.111.031088. Seven days of blood-orange juice: FMD 5.7% to 7.9%, with falls in hs-CRP, IL-6 and TNF-α.
6. Pla-Pagà L, Companys J, Calderón-Pérez L, et al. Effects of hesperidin consumption on cardiovascular risk biomarkers: a systematic review of animal studies and human randomized clinical trials. Nutr Rev. 2019;77(12):845–864. — doi:10.1093/nutrit/nuz036. 12 animal studies and 11 RCTs: endothelial function improved in humans, other biomarkers inconclusive.
7. Testai L, Calderone V. Nutraceutical value of citrus flavanones and their implications in cardiovascular disease. Nutrients. 2017;9(5):502. — doi:10.3390/nu9050502. Mechanistic review of the flavanone class.
8. Chanet A, Milenkovic D, Manach C, Mazur A, Morand C. Citrus flavanones: what is their role in cardiovascular protection? J Agric Food Chem. 2012;60(36):8809–8822. — doi:10.1021/jf300669s.
9. Mas-Capdevila A, Teichenne J, Domenech-Coca C, et al. Effect of hesperidin on cardiovascular disease risk factors: the role of intestinal microbiota on hesperidin bioavailability. Nutrients. 2020;12(5):1488. — doi:10.3390/nu12051488. Why two people drinking the same juice absorb different amounts.
10. Nielsen IL, Chee WS, Poulsen L, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr. 2006;136(2):404–408. — doi:10.1093/jn/136.2.404. Removing the rhamnose sugar bypasses the colonic bottleneck.
11. Cassidy A, Rimm EB, O'Reilly EJ, et al. Dietary flavonoids and risk of stroke in women. Stroke. 2012;43(4):946–951. — doi:10.1161/STROKEAHA.111.637835. Highest versus lowest flavanone quintile, RR 0.81 for ischaemic stroke; total flavonoid intake not associated.
12. Cassidy A, O'Reilly EJ, Kay C, et al. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011;93(2):338–347. — doi:10.3945/ajcn.110.006783. The inconvenient companion: the hypertension signal was anthocyanins from berries, not citrus flavanones.
13. Rangel-Huerta OD, Aguilera CM, Martin MV, et al. Normal or high polyphenol concentration in orange juice affects antioxidant activity, blood pressure, and body weight in obese or overweight adults. J Nutr. 2015;145(8):1808–1816. — doi:10.3945/jn.115.213660.
14. Aptekmann NP, Cesar TB. Long-term orange juice consumption is associated with low LDL-cholesterol and apolipoprotein B in normal and moderately hypercholesterolemic subjects. Lipids Health Dis. 2013;12:119. — doi:10.1186/1476-511X-12-119. Observational, not a trial — read as an association.
15. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice–felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14–23. — doi:10.1067/mcp.2001.113185. Bitter orange behaves like grapefruit; sweet orange does not.
16. Bailey DG, Dresser G, Arnold JM. Grapefruit–medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309–316. — doi:10.1503/cmaj.120951. The furanocoumarin mechanism in full.
17. Cassidy A, Mukamal KJ, Liu L, et al. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013;127(2):188–196. — doi:10.1161/CIRCULATIONAHA.112.122408. Relevant to blood oranges through their anthocyanin content.
18. PubMed topic search — hesperidin and endothelial function: pubmed.ncbi.nlm.nih.gov — hesperidin endothelial function
19. PubMed topic search — citrus flavanone bioavailability: pubmed.ncbi.nlm.nih.gov — flavanone bioavailability

Back to Table of Contents

Connections

• Hesperidin — the compound page, in its own right.
• Anthocyanins — what makes a blood orange red.
• Antioxidants — what the word does and does not mean.
• Oranges — varieties, nutrition and safety.
• Oranges — Benefits Deep Dive
• Folate, Potassium and Blood Pressure — the other half of the orange's blood-pressure story.
• Cardiology & Heart Health
• Atherosclerosis — what endothelial dysfunction leads to.
• Hypertension
• Grapefruit — the citrus with the drug interaction.
• Chen Pi — aged citrus peel, the flavanone-rich tradition.
• Blueberries — the anthocyanin comparison.
• All Food

Back to Table of Contents

Featured Videos